Mustapha Bouhrara1, David A Reiter2, Christopher M Bergeron2, Linda M Zukley3, Luigi Ferrucci4, Susan M Resnick5, Richard G Spencer2. 1. Laboratory of Clinical Investigation, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA. Electronic address: bouhraram@mail.nih.gov. 2. Laboratory of Clinical Investigation, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA. 3. Clinical Research Core, Office of the Scientific Director, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA. 4. Translational Gerontology Branch, National Institutes of Health, Baltimore, MD, USA. 5. Laboratory of Behavioral Neuroscience, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA.
Abstract
INTRODUCTION: We investigated brain demyelination in aging, mild cognitive impairment (MCI), and dementia using a direct magnetic resonance imaging marker of myelin. METHODS: Brains of young and old controls, and old subjects with MCI, Alzheimer's disease, or vascular dementia were scanned using our recently developed myelin water fraction (MWF) mapping technique, which provides greatly improved accuracy over previous comparable methods. Maps of MWF, a direct and specific myelin measure, and relaxation times and magnetization transfer ratio, indirect and nonspecific measures, were constructed. RESULTS: MCI subjects showed decreased MWF compared with old controls. Demyelination was greater in Alzheimer's disease or vascular dementia. As expected, decreased MWF was accompanied by decreased magnetization transfer ratio and increased relaxation times. The young subjects showed greater myelin content than the old subjects. DISCUSSION: We believe this to be the first demonstration of myelin loss in MCI, Alzheimer's disease, and vascular dementia using a method that provides a quantitative magnetic resonance imaging-based measure of myelin. Our findings add to the emerging evidence that myelination may represent an important biomarker for the pathology of MCI and dementia. This study supports the investigation of the role of myelination in MCI and dementia through use of this quantitative magnetic resonance imaging approach in clinical studies of disease progression, and relationship of functional status to myelination status. Furthermore, mapping MWF may permit myelin to serve as a therapeutic target in clinical trials. Published by Elsevier Inc.
INTRODUCTION: We investigated brain demyelination in aging, mild cognitive impairment (MCI), and dementia using a direct magnetic resonance imaging marker of myelin. METHODS: Brains of young and old controls, and old subjects with MCI, Alzheimer's disease, or vascular dementia were scanned using our recently developed myelin water fraction (MWF) mapping technique, which provides greatly improved accuracy over previous comparable methods. Maps of MWF, a direct and specific myelin measure, and relaxation times and magnetization transfer ratio, indirect and nonspecific measures, were constructed. RESULTS: MCI subjects showed decreased MWF compared with old controls. Demyelination was greater in Alzheimer's disease or vascular dementia. As expected, decreased MWF was accompanied by decreased magnetization transfer ratio and increased relaxation times. The young subjects showed greater myelin content than the old subjects. DISCUSSION: We believe this to be the first demonstration of myelin loss in MCI, Alzheimer's disease, and vascular dementia using a method that provides a quantitative magnetic resonance imaging-based measure of myelin. Our findings add to the emerging evidence that myelination may represent an important biomarker for the pathology of MCI and dementia. This study supports the investigation of the role of myelination in MCI and dementia through use of this quantitative magnetic resonance imaging approach in clinical studies of disease progression, and relationship of functional status to myelination status. Furthermore, mapping MWF may permit myelin to serve as a therapeutic target in clinical trials. Published by Elsevier Inc.
Authors: Randy L Buckner; Abraham Z Snyder; Benjamin J Shannon; Gina LaRossa; Rimmon Sachs; Anthony F Fotenos; Yvette I Sheline; William E Klunk; Chester A Mathis; John C Morris; Mark A Mintun Journal: J Neurosci Date: 2005-08-24 Impact factor: 6.167
Authors: Alberto Serrano-Pozo; Matthew P Frosch; Eliezer Masliah; Bradley T Hyman Journal: Cold Spring Harb Perspect Med Date: 2011-09 Impact factor: 6.915
Authors: Christopher M William; Mark L Andermann; Glenn J Goldey; Demetris K Roumis; R Clay Reid; Carla J Shatz; Mark W Albers; Matthew P Frosch; Bradley T Hyman Journal: J Neurosci Date: 2012-06-06 Impact factor: 6.167
Authors: Mark Jenkinson; Christian F Beckmann; Timothy E J Behrens; Mark W Woolrich; Stephen M Smith Journal: Neuroimage Date: 2011-09-16 Impact factor: 6.556
Authors: Mustapha Bouhrara; Diana Y Lee; Abinand C Rejimon; Christopher M Bergeron; Richard G Spencer Journal: J Neurosci Methods Date: 2018-08-18 Impact factor: 2.390
Authors: Suzan Maleki; Yann Chye; Xiaoliu Zhang; Linden Parkes; Samuel R Chamberlain; Leonardo F Fontenelle; Leah Braganza; George Youssef; Valentina Lorenzetti; Ben J Harrison; Murat Yücel; Chao Suo Journal: Psychiatry Res Neuroimaging Date: 2020-02-11 Impact factor: 2.376
Authors: Mustapha Bouhrara; Abinand C Rejimon; Luis E Cortina; Nikkita Khattar; Christopher M Bergeron; Luigi Ferrucci; Susan M Resnick; Richard G Spencer Journal: Neurobiol Aging Date: 2019-10-14 Impact factor: 4.673
Authors: Mustapha Bouhrara; Abinand C Rejimon; Luis E Cortina; Nikkita Khattar; Richard G Spencer Journal: Magn Reson Imaging Date: 2019-11-12 Impact factor: 2.546
Authors: Jian W Dong; Ileana O Jelescu; Benjamin Ades-Aron; Dmitry S Novikov; Kent Friedman; James S Babb; Ricardo S Osorio; James E Galvin; Timothy M Shepherd; Els Fieremans Journal: Neurobiol Aging Date: 2020-01-23 Impact factor: 4.673
Authors: Mustapha Bouhrara; David A Reiter; Michael C Maring; Jean-Marie Bonny; Richard G Spencer Journal: J Neuroimaging Date: 2018-07-12 Impact factor: 2.486